10x Genomics Q3 2026 net loss narrows 29% to $19.43 million

Bitget2026/11/05 21:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10x Genomics' third-quarter 2026 net loss narrowed 29% year-over-year to $19.4 million, while revenue rose to $150.7 million.
Gross margin climbed 8 percentage points to 75% due primarily to lower inventory write-downs and product mix changes.
Global commercial shipments of Atera began, and the new Sentira cloud analysis platform was introduced.
Full-year 2026 revenue guidance increased to $625 million–$635 million from $610 million–$630 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA90509) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

10x Genomics Q3 2026 net loss narrows 29% to $19.43 million

You may also like

Crypto prices